HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Malcolm M. DeCamp Thomas W. Rice Sudish C. Murthy Eugene H. Blackstone Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by DeCamp, M. M. Articles by Blackstone, E. H. Search for Related Content PubMed PubMed Citation Articles by DeCamp, M. M. Articles by Blackstone, E. H. Related Collections Lung - cancer

J Thorac Cardiovasc Surg 2003;126:17-25
© 2003 The American Association for Thoracic Surgery

General thoracic surgery

Value of accelerated multimodality therapy in stage IIIA and IIIB non–small cell lung cancer

^a From the Department of Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
^b the Transplant Center, Division of Surgery, The Cleveland Clinic Foundation, Cleveland, Ohio, USA,
^c Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
^d Department of Radiation Oncology, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
^e Department of Biostatistics and Epidemiology, The Cleveland Clinic Foundation, Cleveland, Ohio, USA.

Read at the Eighty-second Annual Meeting of The American Association for Thoracic Surgery, Washington, DC, May 5-8, 2002.

Received for publication May 9, 2002; accepted for publication January 14, 2003.

^* Address for reprints: Malcolm M. DeCamp, MD, The Cleveland Clinic Foundation, 9500 Euclid Avenue/Desk F25, Cleveland, OH 44195, USA
decampm{at}ccf.org

OBJECTIVES: This study was undertaken to assess accelerated multimodality therapy in patients with IIIA and IIIB non–small cell lung cancer in terms of toxicity, feasibility, response, survival, and recurrence (value) and to identify predictors of pathologic response and improved survival.

METHODS: Between October 1994 and September 2000, a total of 105 patients with stage pIIIA (n = 78) or pIIIB (n = 27) non–small cell lung cancer were enrolled in a study of accelerated multimodality therapy, consisting of hyperfractionated radiotherapy with concurrent chemotherapy (paclitaxel and cisplatin) followed by resection and postoperative chemoradiation. Multivariable correlates of pathologic response and survival were assessed.

RESULTS: Toxic effects related to induction therapy necessitated hospitalization in 40% of patients (n = 42); treatment-related mortality was 9% (n = 9). With respect to feasibility, 100% of patients completed induction therapy, 93% (n = 98) of cancers were operable, 79% (n = 83) of cancers were curatively resectable, and 77% (n = 81) of patients completed all therapy. Sterilization of mediastinal nodes was similar (P = .6) for pN2 (35%) and pN3 (30%) disease. Median, 2-year, and 5-year survivals were 27 months, 53%, and 32%, respectively. Locoregional recurrence, distant recurrence, and both were seen in 6% (n = 6), 45% (n = 47), and 3% (n = 3) of patients, respectively. Pathologic response was not predictable. Nodal status predicted incrementally decreasing survival for patients with cancers downstaged to ypN0 or ypN1 (n = 35) versus ypN2 (n = 44) versus ypN3 (n = 20; P < .001). In addition, advancing age, squamous histologic type, and higher pT predicted poorer survival.

CONCLUSIONS: Accelerated multimodality therapy is equally valuable in IIIA and IIIB non–small cell lung cancers. Despite unpredictable response to induction therapy, younger patients and those with nonsquamous histologic type, sterilization of mediastinal lymph nodes, and lower pT benefit most. A ypN2 stage reduces but does not preclude long-term survival.